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Abstract
Objective: To determine whether a bi-directional relationship exists between depression and HF within a single pop-
ulation of individuals receiving primary care services, using longitudinal electronic health records (EHRs).
Methods: This retrospective cohort study utilized EHRs for adults who received primary care services within a large
healthcare system in 2006. Validated EHR-based algorithms identified 10,649 people with depression (depression
cohort) and 5,911 people with HF (HF cohort) between January 1, 2006 and December 31, 2018. Each person with
depression or HF was matched 1:1 with an unaffected referent on age, sex, and outpatient service use. Each cohort
(with their matched referents) was followed up electronically to identify newly diagnosed HF (in the depression cohort)
and depression (in the HF cohort) that occurred after the index diagnosis of depression or HF, respectively. The risks
of these outcomes were compared (vs. referents) using marginal Cox proportional hazard models adjusted for
16 comorbid chronic conditions.
Results: 2,024 occurrences of newly diagnosed HF were observed in the depression cohort and 944 occurrences of
newly diagnosed depression were observed in the HF cohort over approximately 4–6 years of follow-up. People with
depression had significantly increased risk for developing newly diagnosed HF (HR 2.08, 95% CI 1.89–2.28) and people
with HF had a significantly increased risk of newly diagnosed depression (HR 1.34, 95% CI 1.17–1.54) after adjusting for all
16 comorbid chronic conditions.
Conclusion: These results provide evidence of a bi-directional relationship between depression and HF independently of
age, sex, and multimorbidity from chronic illnesses.
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Introduction
Depression and heart failure (HF) are highly prevalent
chronic conditions. Depression affects over 350 million peo-
ple worldwide and is currently the leading cause of disability
from chronic illness.1 HF affects approximately 5.7 million
U.S. adults, and over 550,000 new cases of HF are diagnosed
each year.2,3 By 2030, it is estimated that more than 8 million
Americans (1 in every 33 people) will have HF.
The co-occurrence of depressive symptoms or syndromes
and cardiovascular disease, most notably coronary heart dis-
ease, is well-documented.4 However, there is more limited
data on the relationship between depression and HF. A meta-
analysis of 27 observational studies found that the prevalence
of depression in patients with HF ranges from 11% to 25% in
outpatients and 35% to 75% in hospitalized patients, and
appears to climb with increasing HF severity.5 The impor-
tance of a depression-HF association rests in the observation
that depression may result in greater functional decline,
higher rehospitalization rates, and higher rates of premature
death in patients with HF—including death by suicide.6
Although depression is common in patients with HF,
little information exists about the directionality of this rela-
tionship. Longitudinal studies have shown that depression
may increase the risk of newly diagnosed HF,7–14 although
others have shown no increased risk.15,16 Longitudinal
studies have also shown a significantly increased incidence
of new-onset depression in people with HF,17,18 thus doc-
umenting an association in the opposite direction. How-
ever, these findings are from separate cohorts. We are
unaware of any large-scale cohort studies focused on the
simultaneous investigation of the temporal association
between depression and HF in a single cohort. To the best
of our knowledge, there is no work to date that has lever-
aged longitudinal health record (EHR) data to study the
associations between depression and HF.
We conducted an electronic health record (EHR)-based
cohort study to test the hypothesis that, within a single
community-based cohort, a bi-directional relationship
exists between depression and HF. As an alternative to the
use of clinical cohorts (which have good phenotyping but
may lack sufficient sample size) and claims databases
(which are large in size but have problems with case accu-
racy), we used EHRs with validated algorithms for identi-
fying depression and HF. For depression, we considered the
impacts of major depressive disorder and other depressive
syndromes that are commonly encountered in routine treat-
ment settings.19,20 For HF, we investigated the association
with new-onset depression—both overall, and in subgroups
defined by preserved or reduced ejection fraction.21
Methods
Study population
The study population consisted of patients 15þ years of age
who were empaneled in Mayo Clinic (Rochester, MN) pri-
mary care practices (internal medicine, family medicine)
for at least 1 month in calendar year 2006 (2006 Primary
Care cohort). The 15þ years of age threshold was based on
the average age of first onset of depression and on the rise
in prevalence rates of non-congenital forms of HF begin-
ning at age 15 years.22,23 To ensure sufficient EHR data,
eligible cohort members had to have at least one medical
visit within 1.5 years after their index date and within the
time frame between 1.5 years and 5 years before their index
date. The Mayo Clinic Institutional Review Board
approved the study prior to data collection.
Study cohorts
In order to examine the bi-directional association between
depression and HF, two cohorts were extracted using EHRs
from the health records of the 2006 Primary Care cohort
members—a depression cohort and a heart failure cohort
(see Figure 1). Each is described below, beginning with the
depression cohort.
Depression cohort. A validated EHR-based algorithm that
utilized a combination of natural language processing and
diagnosis codes was applied to identify cases of depression.
The case definition of depression required the presence of
an ICD-9 diagnosis code (296.2[0–6], 296.3[0–6], 296.82,
298.0, 300.4, or 311) and a depressive disorder term (major
depressive disorder, major depression, depressive disorder,
depression, dysthymic disorder, persistent depressive dis-
order, depressive disorder not otherwise specified [NOS],
depressive disorder not elsewhere classified [NEC]) in the
EHR text. We did not require the presence of an antide-
pressant drug ingredient term in the EHR text or electronic
prescription records given that many depressed patients do
not require pharmacotherapy and can be effectively man-
aged using evidence-based psychosocial treatments.24,25
The EHR-based definition of depression was first validated
in the Primary Care cohort using a random sample of EHRs
from 100 unique patients (50 cases and 50 controls), using
manual records review as a gold standard (PPV 0.76,
NPV 1.0). The algorithm was then applied to the EHR data
from all cohort members through December 31, 2018. For
people with depression, the index date was defined as the
first date during this time window on which the algorithm
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definition was met. People with depression were matched
(by ageþ5 years, sex,þ5 calendar years of index date, and
having at least one outpatient visit during the index year)
with a non-depressed 2006 Primary Care cohort member.
For people without depression, the index date was defined
as the date of the closest clinic visit within 5 years of the
index date for the matched cohort member with depression.
Heart failure cohort. An EHR-based algorithm was also
applied to the 2006 Primary Care cohort through December
31, 2018, to identify people with HF (see Supplemental
Table 1). The HF algorithm, which utilized ICD-9 diagno-
sis codes (ICD-9 428), mentions of HF diagnoses in elec-
tronic inpatient and outpatient clinical notes, and ejection
fraction measurements within 6–12 months of a HF diag-
nosis date, was developed and then validated on a sample of
6,922 records from the Mayo Genome Consortium
(MayoGC)/eMERGE cohort.26 Using manual review of
medical records, the HF algorithm had a PPV of 0.94.26
Where EF data were available, the HF algorithm was also
used to further classify people with HF as having preserved
(HFpEF) and reduced ejection fraction (HFrER), as defined
by an EF cutoff of 50%.27,28 The index date for people with
HF was the first date on which the HF algorithm definition
was met. People with HF were matched by the same para-
meters as for the depression cohort with a 2006 Primary
Care cohort member that did not have HF. For people with-
out HF, the index date was defined using the same proce-
dures as for the depression cohort.
Endpoints
For the depression cohort, the endpoint of interest was
newly diagnosed HF using the EHR-based HF algorithm
described above. For the HF cohort, the endpoint of interest
was newly diagnosed depression using the EHR-based
depression algorithm. Therefore, persons in the depression
cohort with evidence of HF (using the EHR-based HF algo-
rithm) and persons in the HF cohort with evidence of
depression (using the EHR-based depression algorithm)
in the 5 years preceding the index dates were excluded.
Follow-up
Members of the depression and HF cohorts were followed
longitudinally using EHR data from their respective index
dates until the first of the following dates: (a) the end of the
study (December 31, 2018); (b) date of death; (c) date that
one of the study endpoints was reached (newly diagnosed
HF in the depression cohort or newly diagnosed depression
in the HF cohort); or (d) the last follow-up date, defined as
the date of the last primary care visit.
Figure 1. Study design and assembly of cohort of patients who received primary care in the Mayo Clinic (Rochester, MN) 2006 Primary
Care cohort. EHR ¼ electronic health records; HF ¼ heart failure. a A total of 11,711 pairs of individuals who met the algorithm
definition of depression and paired non-depressed referents were identified. Of 11,711 pairs, 161 were dropped due to inability to
match on all parameters, 398 were dropped due to having a HF diagnosis on or within the 5 years preceding the index date (considered
to have prevalent HF), and 646 were dropped due to having zero days of follow-up. A total of 143 pairs were added back after
rematching, bringing the total number of pairs in the depression cohort to 10,649. b A total of 8,288 pairs of individuals who met the
algorithm definition of HF and paired non-HF referents were identified. Of the 8,288 pairs, 270 were dropped due to inability to match
on all parameters, 2,474 were dropped due to having a depression diagnosis on or within the 5 years preceding the index date
(considered to have prevalent depression), and 317 were dropped due to having zero days of follow-up. A total of 684 pairs were added
back after rematching, bringing the total number of pairs in the HF cohort to 5,911.
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We computed a measure of completeness of follow-up for
each cohort as a ratio of the total observed person-time and the
total potential person-time, where potential person-time was
the time from first medical visit until the event of interest, if
one occurred, or the cut-off date where the latter was defined
to be date of the last person in the cohort’s last medical visit.29
For the depression cohort the measure of completeness was
82.1% (84.9% for depression cases and 79.7% for non-
depressed referents); for the heart failure cohort, the measure
of completeness was 92.1% (89.4% for HF cases and 85.8%
for non-HF controls). Measures of completeness were 92.1%
for the depression cohort and 104.5% for the HF cohort after
reassigning the last date to 1 year earlier, indicating that much
of the censoring occurred in the last year rather than being due
to earlier loss to follow-up.
Covariates
Information on age at cohort entry, sex, education level, and
self-reported race were retrieved electronically from the
EHRs of all depression and HF cohort members. Education
level was classified at seven levels: missing information on
education, eighth grade or lower (or 8 years of education);
some high school (9–11 years of education); high school
diploma (12 years of education) or general equivalency
diploma (GED); some college (13–15 years of education);
4-year college degree (16 years of education); and postgrad-
uate (>16 years of education). International Classification of
Diseases (ICD-9, ICD-10) and Hospital International Clas-
sification of Diseases (HICDA) diagnosis codes were also
retrieved electronically for all depression and HF cohort
members, and were grouped into 16 sets of chronic health
conditions (see Supplemental Table 1). The 16 conditions
were selected based on a modification of an original list of
20 chronic conditions recommended to study multimorbid-
ity.30 Depression and HF were excluded because they were
either main exposures or endpoints, depending on which of
the two study cohorts (depression or HF) was under consid-
eration. Human immunodeficiency virus infection and aut-
ism were excluded due to low prevalence in the underlying
population.31 For each condition, we required at least two
diagnosis codes (either the identical code or two different
codes within the same code set) separated by >30 days and
occurring within the 5 years prior to the index date to reduce
false-positive or “suspect” or “rule-out” diagnoses. As a
general measure of multimorbidity, we also calculated a
Charlson Comorbidity Index score for each cohort member,
using previously described methods.32
Statistical analysis
Descriptive statistics were used to summarize the demo-
graphic and clinical characteristics of the study cohorts.
The relationships between depression status at baseline and
newly diagnosed HF during follow-up were assessed using
marginal Cox proportional hazard models, beginning with
univariable models. In the HF cohort, a similar approach
was conducted to test the association between HF status at
baseline and newly diagnosed depression during follow-up.
Multivariable models were then fitted, adjusting for: (1)
Charlson Comorbidity Index scores; (2) a subset of 16
comorbid chronic conditions that were selected using a
step-wise approach (stepwise-adjusted model); and (3) all
16 chronic conditions and education level (fully adjusted
model). For the HF cohort, fully adjusted marginal Cox
modeling was repeated with follow-up time censored at
5 years, to investigate the impact of shorter survival time
in HF patients on the HF-depression association. Stratified
marginal Cox models were run to examine the risk of newly
diagnosed depression in persons with HFpEF and HFrEF.
All analyses were performed using SAS statistical software
(version 9.4, Cary, NC: SAS Institute Inc.).
Results
Individuals with depression and newly diagnosed HF
The demographic and clinical characteristics of depressed
cohort members and those without depression are summar-
ized in Table 1. The depression cohort was predominantly
middle-aged (mean age 49.5 years), Caucasian, and female.
The mean duration of follow-up was similar between
depressed and non-depressed cohort members (Table 1).
In the depression cohort, there were a total of 1,418 indi-
viduals with depression and newly diagnosed HF, and 606
non-depressed individuals with newly diagnosed HF. There
was a significantly higher risk of newly diagnosed HF in
depressed cohort members (HR 2.36, 95% CI 2.15–2.58),
as compared to people without depression (Table 2). As
shown in Table 2, the risk of newly diagnosed HF in depressed
cohort members remained high and statistically significant
after adjusting for Charlson Comorbidity Index score.
Several chronic medical conditions in addition to depres-
sion were also associated univariately with increased risk of
newly diagnosed HF (Supplemental Table 2). As shown in
Table 2, the risk of newly diagnosed HF was significantly
higher in depressed cohort members than non-depressed
cohort members after adjusting for these chronic conditions
in both step-wise and fully adjusted models.
Individuals with HF and newly diagnosed depression
Table 3 summarizes the demographic and clinical charac-
teristics of cohort members with HF and those without HF.
The HF cohort was predominantly elderly and Caucasian,
with a nearly equal proportion of men and women. The
mean duration of follow-up was similar between cohort
members with HF and without HF (Table 3).
A total of 533 people with HF and 411 people without
HF had newly diagnosed depression during follow-up.
There was a significantly higher risk of newly diagnosed
depression for cohort members with HF (HR 1.40, 95% CI
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1.24–1.59) than those without HF (Table 4). The higher risk
of newly diagnosed depression in cohort members with HF
remained statistically significant after adjusting for Charl-
son Comorbidity Index score (Table 4). As shown in Sup-
plemental Table 3, several individual chronic medical
conditions were also associated with newly diagnosed
depression in univariable analyses. Significantly higher
risks of newly diagnosed depression in cohort members
with HF (versus those without HF) were observed after
adjusting for these comorbid conditions in both step-wise
and fully adjusted Cox models (Table 4). The main findings
in the HF cohort were supported by fully adjusted Cox
models censored at 5 years.
Of the 5,911 people with HF, a total of 3,839 (65%) had
EF data. Of these, 2,706 people with HF had EF  50% and
were classified as having HFpEF. The remaining 1,133
Table 1. Characteristics of 10,649 people with depression and 10,649 people without depression in the 2006 Primary Care cohort.
With Depression Without Depressiona
N ¼ 10,649 N ¼ 10,649
Mean (SD) Mean (SD)
Age, yrs. 49.5 (19.1) 49.5 (19.1)
Charlson comorbidity index scoreb 1.6 (2.2) 1.3 (1.9)
Follow-up time, years 6.3 (3.7) 6.4 (3.7)
N (%) N (%)
Female sex 6,353 (59.7) 6,353 (59.7)
Race
Caucasian 9,771 (91.8) 9,607 (90.2)
African-American/Black 255 (2.4) 216 (2.0)
Asian 217 (2.0) 355 (3.3)
American Indian/Alaskan native 27 (0.3) 11 (0.1)
Hawaiian/Pacific Islander 8 (0.1) 10 (0.1)
Other 259 (2.4) 206 (1.9)
Unknown/missingc 112 (1.1) 244 (2.3)
Education level
Eighth grade or lower 240 (2.6) 180 (1.9)
Some high school 392 (4.2) 279 (2.9)
High school graduate/GEDd 2,340 (25.2) 2,113 (22.0)
Some college 3,094 (33.3) 2,976 (31.0)
Four-year college degree 1,834 (19.8) 2,206 (23.0)
Postgraduate education/degree 1,383 (14.9) 1,832 (19.1)
Missing/unknown 1,366 1,063
Comorbid chronic illnessese
Obesity, diagnosed 328 (3.1) 176 (1.7)
Atrial fibrillation 265 (2.5) 218 (2.0)
Arthritis 148 (1.4) 114 (1.1)
Asthma 655 (6.2) 476 (4.5)
Cancer 1,457 (13.7) 1,235 (11.6)
Chronic kidney disease 390 (3.7) 192 (1.8)
Chronic pulmonary disease 404 (3.8) 226 (2.1)
Dementia 272 (2.6) 81 (0.8)
Diabetes mellitus 1,766 (16.6) 1,422 (13.4)
Hepatitis 67 (0.6) 37 (0.3)
Hyperlipidemia 3,007 (28.2) 2,664 (25.0)
Hypertension 2,874 (27.0) 2,380 (22.3)
Ischemic heart disease 15 (0.1) 4 (0.0)
Osteoporosis 488 (4.6) 387 (3.6)
Schizophrenia 53 (0.5) 9 (0.1)
Stroke/cerebrovascular accident 289 (2.7) 153 (1.4)
There was no missing data for age, Charlson comorbidity index score, or sex; or for the 16 comorbid chronic illnesses.
aPeople with depression were matched with non-depressed 2006 Primary Care cohort members on age þ 5 years, sex, having at least one outpatient
visit during a window of þ 5 years of the study year, and having at least one primary care outpatient visit within 1.5 years of their index date and within
the time frame between 1.5 years and 5 years before their index date.
bRefers to Charlson Comorbidity Index score (severity- and age-weighted sum of diseases).
cUnknown/missing race included 54 depressed cohort members and 172 non-depressed cohort who chose not to disclose their race.
dGeneral equivalency degree (GED).
eDefined using International Classification of Diseases (ICD) and Hospital Adaptation of the International Classification of Diseases (HICDA) diagnosis
codes, as shown in Supplemental Table 1.
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patients had EF < 50% and were classified as having HFrEF.
In both step-wise and fully adjusted Cox models, the risk of
newly diagnosed depression was significantly higher in
cohort members with HFrEF (step-wise HR 2.08, 95% CI
1.56–2.76; fully adjusted HR 1.96, 95% CI 1.45–2.64) and
those with HFpEF (step-wise HR 1.57, 95% CI 1.30–1.91;
fully adjusted HR 1.57, 95% CI 1.28–1.92), as compared to
people without HF (Supplemental Tables 4 and 5).
Discussion
Prior research has focused on the associations between
newly diagnosed HF in depressed patients or on newly
diagnosed depression in people with HF using separate,
smaller cohorts. To our knowledge, this study is the first
to simultaneously examine the temporal, bi-directional
association between depression and HF within a single
Table 2. Hazard ratios (HR) (95% CI) for the risk of newly
diagnosed heart failure (HF) according to depression status in




















Depressed 2.03 1.84 2.23 <0.0001
Non-depresseda Ref.
Fully adjusted for comorbid
conditionsc
Depressed 2.03 1.84 2.23 <0.0001
Non-depresseda Ref.
The impact of depression on subsequent HF diagnosis was assessed using
marginal Cox proportional hazard models.
aPeople with depression were matched with non-depressed 2006 Primary
Care cohort members on age þ 5 years, sex, having at least one out-
patient visit during a window ofþ 5 years of the study year, and having at
least one primary care outpatient visit within 1.5 years of their index date
and within the time frame between 1.5 years and 5 years before their
index date.
bComorbid conditions were defined using ICD-9, ICD-10, and HICDA
diagnosis codes (see Supplemental Table 1). Covariates selected by step-
wise algorithm included education level, hypertension, chronic pulmon-
ary disease, atrial fibrillation, diabetes mellitus, cancer, osteoporosis,
asthma, hyperlipidemia, dementia, hepatitis, chronic kidney disease,
stroke/cerebrovascular accident, and arthritis.
cComorbid conditions were defined using ICD-9, ICD-10, and HICDA
diagnosis codes (see Supplemental Table 1). Covariates included in the
fully adjusted model included education level, hypertension, ischemic
heart disease, chronic pulmonary disease, atrial fibrillation, diabetes mel-
litus, cancer, osteoporosis, asthma, hyperlipidemia, dementia, hepatitis,
chronic kidney disease, stroke/cerebrovascular accident, arthritis, diag-
nosed obesity, and schizophrenia.
Table 3. Characteristics of 5,911 people with heart failure (HF)
and 5,911 people without HF in the 2006 Primary Care cohort.
With HF Without HFa
N ¼ 5,911 N ¼ 5,911
Mean (SD) Mean (SD)
Age, yrs. 70.3 (15.2) 70.2 (15.1)
Charlson comorbidity index scoreb 4.1 (2.6) 3.3 (2.2)
Follow-up time, years 3.6 (3.1) 3.9 (3.2)
N (%) N (%)
Female sex 3,004 (50.8) 3,004 (50.8)
Race
Caucasian 5,611 (94.9) 5,615 (95.0)
African-American/Black 92 (1.6) 63 (1.1)
Asian 93 (1.6) 122 (2.1)
American Indian/Alaskan native 5 (0.1) 3 (0.1)
Hawaiian/Pacific Islander 1 (0.0) 1 (0.0)
Other 79 (1.3) 60 (1.0)
Unknown/missingc 30 (0.5) 47 (0.8)
Education level
Eighth grade or lower 326 (6.1) 223 (4.1)
Some high school 274 (5.1) 159 (2.9)
High school graduate/GEDd 1,893 (35.3) 1,622 (29.6)
Some college 1,466 (27.4) 1,522 (27.7)
Four-year college degree 682 (12.7) 918 (16.7)
Postgraduate education/degree 718 (13.4) 1,041 (19.0)
Missing/unknown 552 426
Comorbid chronic illnessese
Obesity, diagnosed 504 (8.5) 198 (3.3)
Atrial fibrillation 1,070 (18.1) 281 (4.8)
Arthritis 205 (3.5) 112 (1.9)
Asthma 844 (14.3) 250 (4.2)
Cancer 1,665 (28.3) 1,501 (25.4)
Chronic kidney disease 979 (16.6) 324 (5.5)
Chronic pulmonary disease 830 (14.0) 237 (4.0)
Dementia 310 (5.2) 324 (5.5)
Diabetes mellitus 2,394 (40.5) 1,764 (29.8)
Hepatitis 62 (1.0) 37 (0.6)
Hyperlipidemia 3,558 (60.2) 3,025 (51.2)
Hypertension 3,884 (65.7) 2,901 (49.1)
Ischemic heart disease 68 (1.2) 20 (0.3)
Osteoporosis 663 (11.2) 580 (9.8)
Schizophrenia 82 (1.4) 45 (0.8)
Stroke/cerebrovascular accident 515 (8.7) 273 (4.6)
There was no missing data for age, Charlson comorbidity index score, or
sex; or for the 16 comorbid chronic illnesses.
aPeople with HF were matched with 2006 Primary Care cohort members
without HF on ageþ 5 years, sex, having at least one outpatient visit during
a window of þ 5 years of the study year, and having at least one primary
care outpatient visit within 1.5 years of their index date and within the time
frame between 1.5 years and 5 years before their index date.
bRefers to Charlson Comorbidity Index score (severity- and age-weighted
sum of diseases).
cUnknown/missing race included 20 cohort members with HF and 26
without HF who chose not to disclose their race.
dGeneral equivalency degree (GED).
eDefined using International Classification of Diseases (ICD) and Hospital
Adaptation of the International Classification of Diseases (HICDA) diag-
nosis codes, as shown in Supplemental Table 1.
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population using longitudinal data derived from EHRs. The
findings from this well-characterized cohort of 10,649
patients with diagnosed depression, 5,911 patients with
diagnosed HF, and equal numbers of matched non-
depressed or non-HF patients, provided evidence of a
bi-directional relationship between depression and HF.
These bi-directional associations remained significant after
adjusting for numerous general medical and mental health
comorbidities, and for overall chronic disease burden.
Depression status and newly diagnosed HF
In our study, depression was strongly associated with an
increased likelihood of newly diagnosed HF, after account-
ing for the potential effects of age, sex, and medical and
psychiatric comorbidity. Although some have failed to
demonstrate a significantly increased risk of HF in people
with depressive disorders or symptoms,15,16 our results are
consistent with findings from the majority of longitudinal
studies showing a significantly increased risk of HF in
people with diagnosed major depression,13 depressive syn-
dromes,8 and depressive symptoms.7,9–12,14
Our depression case definition included multiple unipo-
lar depression diagnoses rather than focusing solely on
major depression. This decision was based on evidence
from epidemiological studies showing that clinically sig-
nificant depressive symptoms are two to three times more
prevalent than major depression across a variety of treat-
ment settings,20 and that the impact of depressive disorders
on health status does not differ significantly between syn-
dromal forms of depression.33–35 Depression severity, how-
ever, appears to impact the risk of HF and HF outcomes.
A large prospective study of more than 62,000 adults
showed that the risk of newly diagnosed HF increased with
increasing depression severity.9 Other studies have shown
that all-cause mortality and the risk of rehospitalization are
higher in people with HF and major depression than HF
patients with minor or mild depression.36,37 Although
several cohort members in our study had depression scale
scores that were available for abstraction, this information
was not complete enough to conduct a valid analysis of HF
risk by depression severity.
Regardless of how it is defined, depression is associated
with co-occurring chronic illnesses that may be expected to
increase the risk of HF.38,39 Therefore, the association
between depression and HF is subject to confounding by
comorbidity. Our adjusted models included 16 common
chronic conditions that often co-occur with depression and
HF.40,41 The association between depression and newly
diagnosed HF remained significant after controlling for
these conditions, and the strength of association between
depression and newly diagnosed HF in our univariable
model attenuated to only a minor degree in the adjusted
models. Taken together, our findings suggest that depres-
sion increases the risk of HF independently of co-occurring
chronic somatic and mental health conditions.
We studied the effect of depression on HF risk across a
relatively wide age range. In our study, the inter-quartile
age range was 33–64 years—an important consideration
given the relatively young age of onset for most depressive
disorders,42 and increasing recognition of HF in middle-
aged and younger persons.43 The increased risk of HF in
depressed persons in our study is troubling given that the
mean age and average duration of follow-up in our depres-
sion cohort was 49.5 and 6.3 years, respectively; yet, peo-
ple at or above the age of 65 years account for over 80% of
prevalent HF cases in the U.S. and Europe.44 Indeed,
depression has been hypothesized as leading to the earlier
onset (or more rapid accumulation) of age-associated
comorbidity, a proxy for accelerated aging,45,46 than non-
depressed persons.47 Recent studies have also shown that
depression is associated with shorter telomere length,48 a
Table 4. Hazard ratios (HR) (95% CI) for the risk of newly
diagnosed depression according to heart failure status in the












Heart failure 1.40 1.24 1.59 <0.0001
No heart failurea Ref.
Adjusted for Charlson
Comorbidity index
Heart failure 1.38 1.21 1.58 <0.0001
No heart failurea Ref.
Adjusted for comorbid
conditions (stepwise)b
Heart failure 1.32 1.15 1.50 <0.0001
No heart failurea Ref.
Fully adjusted for comorbid
conditionsc
Heart failure 1.31 1.14 1.50 <0.0001
No heart failurea Ref.
The impact of HF on subsequent depression diagnosis was assessed using
marginal Cox proportional hazard models.
aPeople with HF were matched with 2006 Primary Care cohort members
without HF on age þ 5 years, sex, having at least one outpatient visit
during a window of þ 5 years of the study year, and having at least one
primary care outpatient visit within 1.5 years of their index date and
within the time frame between 1.5 years and 5 years before their index
date.
bComorbid conditions were defined using ICD-9, ICD-10, and HICDA
diagnosis codes (see Supplemental Table 1). Covariates selected by step-
wise algorithm included education level, hypertension, chronic pulmon-
ary disease, cancer, osteoporosis, asthma, hyperlipidemia, and arthritis.
cComorbid conditions were defined using ICD-9, ICD-10, and HICDA
diagnosis codes (see Supplemental Table 1). Covariates included in the
fully adjusted model included education level, hypertension, ischemic
heart disease, chronic pulmonary disease, atrial fibrillation, diabetes mel-
litus, cancer, osteoporosis, asthma, hyperlipidemia, dementia, hepatitis,
chronic kidney disease, stroke/cerebrovascular accident, arthritis, diag-
nosed obesity, and schizophrenia.
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measure of cellular aging, and that such effects appear to be
most pronounced for people with more severe and chronic
major depression.49 A number of other biological mediators
of aging are implicated in the pathophysiology of depressive
syndromes and HF, inviting speculation about shared neu-
roendocrine, inflammatory, genetic, epigenetic, and cellular
mechanisms50,51—important areas of potentially shared dis-
ease vulnerability that are in need of further study.
HF status and newly diagnosed depression
In our study, there was a significantly increased risk of
newly diagnosed depression in people with HF, as compared
to those without HF. The heightened risk of newly diagnosed
depression in HF patients also occurred independently of
age, sex, and medical and psychiatric comorbidity. The esti-
mated associations between HF status and newly diagnosed
depression from univariable models attenuated only slightly
in step-wise and fully adjusted models. Taken together, these
results established the independent and bi-directional asso-
ciation between depression and HF in this cohort.
There is surprisingly little evidence from longitudinal
studies pointing to increased risk of developing depression
in people with HF. Our results are consistent with those of a
cohort study of 5,095 elderly adults that documented asso-
ciations between HF and new-onset clinically significant
depressive symptoms and syndromes as a composite end-
point, and depressive syndromes separately.52 Others have
documented a high incidence of newly diagnosed depres-
sive syndromes or clinically significant depressive symp-
toms in people with HF, ranging from 6% (major
depression) to 21% (depressive symptoms).17,18 Our results
add to a growing evidence base pointing to a heightened
risk of newly diagnosed depression in people with HF.
The risk of newly diagnosed depression was signifi-
cantly increased in people with HFpEF and those with
HFrEF. Our findings are consistent with cross-sectional
data showing that depression occurs commonly in patients
with HFrEF and HFpEF,53 and with the results of a long-
itudinal study showing that depression predicts worse out-
comes in people with both HF subtypes—including
increased risk of cardiac death and HF rehospitalization
over 2 years of follow-up.54 To our knowledge, this is the
first longitudinal EHR-based study documenting the rela-
tionship between newly diagnosed depression in people
with HFpEF and HFrEF, separately. In our study, the asso-
ciation between HF and newly diagnosed depression
appeared to be stronger for the HFrEF individuals. It is
presently unknown if HFrEF truly has a stronger relation-
ship with depression than HFpEF, although several factors
could account for such a finding. These include the strong
associations between coronary artery disease and both
depression and HFrEF,55 and possible shared downstream
effects of excessive neurohormonal and inflammatory
activities that may serve as underlying pathophysiological
factors for both depression and pathological cardiac
remodeling associated with HFrEF.56,57 Only 65% of peo-
ple in our HF cohort had data on ejection fraction, which
limits the conclusions one can draw from this study about
the relationships between HF subtype (based on ejection
fraction) and the risk of newly diagnosed depression.
Implications
The evidence of a bi-directional association between
depression and HF in this study and the known adverse
impacts of each condition on important longitudinal out-
comes of the other highlight the important public health
implications of our results. Both depression and HF are
considered to be preventable and treatable conditions, sug-
gesting that aggressively treating depression may reduce
the occurrence of HF and vice-versa, provided that these
illnesses are causally related. A bi-directional causal asso-
ciation seems plausible based on the existence of a number
of potentially shared biological58–62 and behavioral factors
in depression and HF that are related to pathophysiology
and worse longitudinal outcome for both conditions.63–65
The importance of shared etiopathophysiological mechan-
isms and outcome-modifying factors between depression
and HF rests in the possibility that early interventions for
one condition may also prevent or provide benefit for the
other. For instance, the occurrence of depression in people
with HF negatively impacts adherence to medication, car-
diac rehabilitation, and other forms of treatment;65 and
there are important potential “downstream” impacts on
healthcare use and costs of care that are in need of further
investigation. However, there are still well-known chal-
lenges that remain with respect to leveraging existing treat-
ment modalities for reducing depressive symptoms in HF
patients and showing benefit for HF-specific outcomes
when depressive symptoms improve or remit.66,67 In
addition, though well-tolerated, flexibly dosed sertraline
(50–200 mg daily) failed to demonstrate significant anti-
depressive benefit versus placebo over 12 weeks of treat-
ment in 469 depressed HF patients (New York Heart
Association functional class II to IV) who participated in the
Sertraline Against Depression and Heart Disease in Chronic
Heart Failure (SADHART-CHF) Trial.68 Such observations
may weaken a causal link between depression and HF. Addi-
tionally, it has yet to be convincingly demonstrated that
reduced HF symptoms leads directly to improvement in
depression when the two conditions co-occur. In this work,
we were able to establish bi-directional associations between
depression and HF, but not causality given the observational
study design. We were also unable to assess the effects of
successful treatment of depression on the risk of newly diag-
nosed HF, or vice-versa, in this study.
Strengths and limitations
Our EHR-based cohort study had notable strengths. People
with depression and HF were carefully matched to
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unaffected referent patients in each of the study cohorts,
and our analyses robustly accounted for physical and men-
tal health multimorbidity. The data source for this study
permitted the simultaneous testing of two hypotheses—that
depression was associated with newly diagnosed HF and
that HF was associated with newly diagnosed depression—
in a single population of patients receiving medical care in
routine primary care settings. The use of EHRs allowed for
the comprehensive ascertainment of study data that
spanned the full range of medical care for each cohort
member, and permitted access to information with suffi-
cient detail to accurately define people with depression,
people with HF, and confounding factors that included a
wide range of chronic illnesses.
There were also limitations to our approach, in addition
to those already discussed. The data for our study consisted
of information in EHRs (including free text and diagnosis
codes). Although the records were comprehensive, they
were not collected for research purposes, and are thus sub-
ject to misclassification. However, misclassification in this
study was likely to be non-differential, so any resulting bias
would be toward the null. Our study cohorts were selected
from calendar year 2006, which assured reasonably com-
plete data from the electronic health records and an ade-
quate amount of follow-up time. Secular trends in the
diagnosis, treatment and prognosis of depression and HF,
however, could have impacts on the strength of association
between these two conditions as a function of time,
although we anticipate that such effects may have been
minimized, at least partially, by matching on calendar year
at index date. We lacked complete access to data on impor-
tant covariates, such as smoking, body mass index, and
dietary/health behaviors. We used level of education as a
broad measure of socioeconomic status, given the lack of a
more direct measure.69 Future studies of the relationship
between depression and HF will need to account for the
potential effects of more nuanced indicators of socioeco-
nomic status given its predictive effects on the develop-
ment of both conditions.70,71 We did not have complete
data on lifetime depression. Therefore, the algorithms used
to define depression may have identified recurrences of
depression rather than new cases.72 Future studies with
sound psychiatric assessments and follow-up starting in
early adulthood are needed to better-establish a link
between depression and HF. Associations in the other
direction (depression to HF) are less-problematic given that
HF is non-episodic and emerges later in life. The discre-
pancy in follow-up times between the depression and HF
cohorts also warrants further discussion because of the rea-
sonably high likelihood that it reflects differences in survi-
vorship. Although we demonstrated a significant
association between HF and newly diagnosed depression,
we did not have data on comparative death rates between
the study cohorts, which may have been helpful for deter-
mining if depletion of susceptible persons (for developing a
diagnosed episode of depression) may have led to an
underestimation of the risk of newly diagnosed depression
in the HF cohort. Only a small number of depression and
HF cohort members in our study had diagnosed ischemic
heart disease at baseline, which may have resulted in an
underestimation of the relationship between depression and
HF in either direction.73,74 However, our findings in
adjusted models that included ischemic heart disease were
in accord with separate models that adjusted for Charlson
Comorbidity Index scores, the latter of which included
myocardial infarction and correlated conditions such as
peripheral vascular disease, cerebrovascular disease, and
diabetes with evidence of end organ damage. Our cohort
consisted of mainly Caucasian individuals actively receiv-
ing primary care services within a single healthcare system
located in southeast Minnesota. Therefore, our findings
may not generalize to non-care-seeking individuals, or to
more racially and ethnically diverse populations residing
elsewhere. And finally, although the association between
depression and HF appeared to be stronger in the depres-
sion cohort than the HF cohort, this may reflect differences
in survivorship between the two cohorts. Therefore, our
results should not be interpreted as conclusive evidence
of a difference in the strength of associations between these
very different groups of patients.
Conclusion
This large, well-controlled cohort study using longitudinal
EHR data provides evidence that the relationship between
depression and HF is bi-directional, and that it occurs inde-
pendently of age, sex, and multimorbidity from common
chronic illnesses. The risk of newly diagnosed depression
appears to be increased in people with HFrEF and in people
with HFpEF.
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